Blue light cystoscopy reduces bladder cancer recurrence risk by 38% compared to white light cystoscopy, as shown in the BRAVO study. The BRAVO study used real-world data from 626 veterans, confirming ...

(StatePoint) When John noticed blood in his urine, he consulted his doctor and was quickly referred to a urologist. (John is a composite character, based on the experiences of real-life patients.) ...

Bladder cancer affects more than 86,000 people in the United States each year, according to the American Cancer Society, with the majority being over age 55. And while the disease can often be ...

In patients with suspected muscle-invasive bladder cancer (MIBC), definitive treatment can be expedited by adding multi-parametric magnetic resonance imaging (mpMRI) to flexible cystoscopic biopsy at ...

Cystoscopy without the aid of urinary markers is the most cost-effective strategy for detecting recurrence of non-invasive bladder cancer, according to researchers. In a study that examined five ...

A new urine test could spare bladder cancer survivors from a painful follow-up procedure needed to ensure their cancer hasn't come back, researchers report. People who've gotten surgery for high-risk ...

A simple urine test can more than halve the number of cystoscopies necessary to follow up high-risk bladder cancer patients, new research has found. Cystoscopies involve inserting a flexible probe ...

A urine test was shown to decrease the need for invasive cystoscopies in patients with non-muscle-invasive bladder cancer. A urine-based test may decrease the number of invasive cystoscopies in ...

PARIS — Should clinicians promote active surveillance for non–muscle-invasive bladder tumors (NMIBT) and establish it as a comprehensive management approach, as with prostate and kidney cancers?

In a trial, Xpert® Bladder Cancer Monitor, a non-invasive urinary biomarker test, appeared suitable for guiding cystoscopy during monitoring of patients with NMIBC. Alternating between cystoscopy and ...